The drug, glibenclamide, for example, inhibits both Kir6.2/SUR1 and Kir6.1/SUR2B with approximately equal potency and therefore cannot be used to treat vascular disorders due to its risk of also inducing hypoglycemia [12,14]. The gene discussed is KCNJ8; the disease is vascular disorder.